Pulse Biosciences Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pulse Biosciences stock.
View analyst ratings for Pulse Biosciences or view top-rated stocks.

Wall Street analysts have given Pulse Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pulse Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Pulse Biosciences.

Pulse Biosciences, Inc. (NASDAQ:PLSE) announced its quarterly earnings data on Sunday, February, 21st. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.09.
View Pulse Biosciences' earnings history.

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PLSE shares have increased by 227.7% and is now trading at $20.84.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued twelve-month target prices for Pulse Biosciences' shares. Their forecasts range from $40.00 to $46.00. On average, they anticipate Pulse Biosciences' share price to reach $43.00 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price.
View analysts' price targets for Pulse Biosciences or view top-rated stocks among Wall Street analysts.

2 employees have rated Pulse Biosciences CEO Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among Pulse Biosciences' employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Pulse Biosciences include Inovio Pharmaceuticals (INO), Silk Road Medical (SILK), GenMark Diagnostics (GNMK), Luminex (LMNX), Alphatec (ATEC), Cardiovascular Systems (CSII), Pulmonx (LUNG), MiMedx Group (MDXG), Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), Cerus (CERS), LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS) and AngioDynamics (ANGO).
View all of PLSE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), (CGC), Enphase Energy (ENPH) and Novavax (NVAX).

(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (0.12%).
View institutional ownership trends for Pulse Biosciences.

PLSE stock was acquired by a variety of institutional investors in the last quarter, including Westside Investment Management Inc..
View insider buying and selling activity for Pulse Biosciences or or view top insider-buying stocks.

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLSE stock can currently be purchased for approximately $20.84.

Pulse Biosciences has a market capitalization of $543.65 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

Pulse Biosciences employs 95 workers across the globe.

The official website for Pulse Biosciences is www.pulsebiosciences.com.

Pulse Biosciences is headquartered at 3957 POINT EDEN WAY, HAYWARD CA, 94545.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]